Can-Fite BioPharma American Depositary Shares
CANF
9 hedge funds and large institutions have $1.9M invested in Can-Fite BioPharma American Depositary Shares in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
50% more funds holding
Funds holding: 6 → 9 (+3)
8% more capital invested
Capital invested by funds: $1.77M → $1.9M (+$135K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Taylor Asset Management
Toronto,
Ontario, Canada
|
+$220K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$33.8K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
+$25.4K |
| 4 |
MC
Menta Capital
San Francisco,
California
|
+$16.9K |
| 5 |
Morgan Stanley
New York
|
+$16.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$30K |
| 2 |
MFS
MSI Financial Services
Springfield,
Massachusetts
|
-$3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TAM
1
Taylor Asset Management
Toronto,
Ontario, Canada
| $1.61M | +$220K | +26 | +14% |
|
|
MC
2
Menta Capital
San Francisco,
California
| $116K | +$16.9K | +2 | +15% |
|
|
VKH
3
Virtu KCG Holdings
New York
| $70K | +$33.8K | +4 | +80% |
|
|
ARTA
4
A.R.T. Advisors
New York
| $41K | +$8.46K | +1 | +25% |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| $23K | +$25.4K | +3 | New |
|
6
UBS Group
Zurich,
Switzerland
| $16K | +$16.9K | +2 | New |
|
|
7
Morgan Stanley
New York
| $14K | +$16.9K | +2 | New |
|
|
PCM
8
Prelude Capital Management
New York
| $7K | +$8.46K | +1 | New |
|
9
Group One Trading
Chicago,
Illinois
| $5K | – | – | – |
|
|
10
Jane Street
New York
| – | -$30K | -4 | Closed |
|
|
MFS
11
MSI Financial Services
Springfield,
Massachusetts
| – | -$3K | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| – | -$1K | – | – |
|
CANF Hedge Fund Activity: Q2 2016 in Review
9 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q2 2016, worth a combined $1.9M — up 7.6% from $1.77M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CANF positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Taylor Asset Management, adding an estimated $220K. The largest seller was Jane Street, exiting entirely with an estimated $30K sold.
- 9 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q2 2016, up from 6 in Q1 2016.
- Funds reported $1.9M of Can-Fite BioPharma American Depositary Shares stock for Q2 2016, up 7.6% quarter-over-quarter.
- 4 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q2 2016 and 1 closed out, a net change of +3 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q2 2016 was Taylor Asset Management, an estimated $220K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q2 2016 was Jane Street, an estimated $30K sold.
Based on aggregated 13F filings for Q2 2016.